A AB BS S T TR RA AC CT T O Ob b j je ec c t ti i v ve e: : Psoriasis is a chronic, inflammatory and hyperproliferative immune-mediated skin disorder. Psoriatic arthritis is an important comorbidity observed in patients with psoriasis. We aimed to evaluate the importance of some autoantibodies and anti-cyclic citrullinated peptide (-CCP) antibodies in patients with psoriasis vulgaris (PsV) and psoriatic arthritis (PsA), and to contribute to the immunopathogenesis of psoriasis. M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : Forty four PsV and 45 PsA patients, and 32 healthy volunteers were included in the study. Peripheral venous blood samples were collected from patients and healthy volunteers. In serum samples, Anti-CCP antibodies were studied semi-quantitatively, anti-neutrophil cytoplasmic antibody (ANCA) profiles quantitatively with ELISA method, and antinuclear antibody (ANA) profiles were studied quantitatively by immunoblotting. R Re es su ul lt ts s: : Totally 8 (8.9%) patients (2 PsA and 6 PsV) were anti-CCP positive. ANCA positivity was not detected in any of our PsV or PsA patients. A 43-year-old woman with PsA was AMA-M2(+), anti-Ro52(++), anti-nucleosome(+), anti-ds DNA(+). A 38-year-old man with PsV had suspicious anti-nRNP/-Sm positivity (in gray zone); a 33-year-old woman with PsV had anti-SS-A positivity. C Co on nc cl lu us si io on n: : In our study, patients with PsA had less frequent anti-CCP positivity compared to the present data in the literature. ANCA positivity was not detected in any of our patients. ANA profile antibodies were detected only in three patients. Consequently, it is thought that larger scale, multicentered studies are needed in order to enlighten the role of anti-CCP antibodies and other autoantibodies in the immunopathogenesis of psoariasis and psoriatic arthritis.
Feride GÖĞÜŞ, P so ri a sis is a chro nic, inf lam ma tory and hyper pro li fe ra ti ve skin di se a se with a ge ne tic ba sis. 1 The know led ge ga i ned over the past 3 de ca des lets us pos tu la te that pso ri a sis is an immu no lo gi cally in du ced di se a se in which va ri o us cells play a do mi nant ro le at dif fe rent sta ges. 1 Psori a tic art hri tis (PsA) has be en clas si cally de fi ned as an inf lam ma tory art hri tis as so ci a ted with pso ri a sis that sha res many fe a tu res of rhe u ma to id art hri tis (RA). 2, 3 The re fo re, it is very dif fi cult to ma ke a diffe ren ti al di ag no sis bet we en PsA and RA in a pa tient with pso ri a sis. 3 In com pa ri son with ot her re le vant inf lam ma tory art hro pat hi es, in which a de fi ni te di ag no sis is fre qu ently pos sib le only by me ans of la bo ra tory in ves ti ga ti ons, in PsA tru e labo ra tory di ag nos tic mar kers are lac king. 2 Ho wever, in a mo re ac cu ra te ap pro ach, la bo ra tory in ves ti ga ti ons may of fer im por tant ad di ti o nal to ols to bet ter in ter pret the va ri o us and he te ro ge no us spec trum of the di se a se ex pres si on of PsA. La bo ratory in ves ti ga ti ons may be used to ob ta in in for mati on in the fi elds of di ag no sis, di se a se ac ti vity, prog no sis and eva lu a ti on of the ef fects of the rapy.
Cit rul li ne is a de a mi na ted and post-trans la ti onally mo di fi ed de ri va ti ve of ar gi ni ne. 4 The tran siti on from ar gi ni ne to cit rul li ne is ca taly zed by pep tidy lar gi ni ne-de i mi na se (PAD) that has fi ve iso forms in mam mals. 4 Tis su e cit rul li na ti on is a physi o lo gi cal pro cess un derl ying epit he li al ke ra tini za ti on, inf lam ma ti on and in cre a sed apop to sis which are al so very im por tant pro ces ses in the patho ge ne sis of pso ri a sis. 5 The re is re la ti vely small amo unt of cit rul li na ted pro te ins in the nor mal syno vi al tis su e, whe re as ac ti ve cit rul li na ti on has be en as so ci a ted with syno vi tis. 6 Cit rul li na ted prote in epi to pes ha ve be en iden ti fi ed in ex tra vas cular fib rin de po sits and ex tra cel lu lar fib ri no gen ag gre ga tes wit hin the RA syno vi um. 7 Fi lag grin, the first cit rul li na ted pro te in iden ti fi ed, as po tenti al au to an ti gen in RA is an epi der mal pro te in that is usu ally ab sent in the syno vi um. 8 Thus, ot her citrul li na ted pro te ins, such as fib rin or vi men tin that are abun dantly ex pres sed and cit rul li na ted in syno vi al tis su es may dri ve au to an ti body pro duc ti on.
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The se au to an ti gens in du ce the pro duc ti on of an ticit rul li na ted pro te in/pep ti de (an ti-CCP) au to an tibo di es that ha ve be en as so ci a ted with au to im munity un derl ying RA. 10 The gro up of an ti-CCP an tibo di es has al so be en re fer red to as an ti-fi lag grin an ti bo di es pre vi o usly. 7 Sin ce the pat ho ge ne sis of pso a ri a sis is highly as so ci a ted with inf lam ma ti on and fib rin for ma ti on, we pro po sed that the se citrul lin na ted pro te ins might be im por tant au to an tigens in the unk nown eti o pat ho ge ne sis of pso ri a sis and pso ri a tic art hri tis al so.
Alt ho ugh most stu di es sug gest high di ag nos tic spe ci fi city and sen si ti vity of an ti-CCP an ti bo di es in RA tis su e, cit rul li na ti on and an ti-CCP pro duc ti on ha ve be en de tec ted in pa ti ents with ot her types of art hri tis, but less fre qu ently. 5, 6, [11] [12] [13] Be si des, an ti-CCP ti ter has be en shown to be an early prog nostic mar ker to pre dict RA. 14 The re is al so a gro wing in te rest re gar ding the pre va len ce and cli ni cal impor tan ce of an ti-CCP an ti bo di es in PsA. 12 In ad diti on to be ing use ful in di ag no sis, an ti-CCP an ti bo di es might be an in di ca tor of prog no sis and di se a se se ve rity in PsA as in RA. Re cently, so me cli ni cal tri als ha ve re ve a led the pre sen ce of an ti-CCP in PsA pa ti ents in 5.6-15.7%. 15 Alt ho ugh anti-CCP an ti bo di es are highly spe ci fic for RA, the ir ro le in PsA re ma ins unc le ar. 16 Eti o pat ho ge ne sis of pso ri a sis has not be en comp le tely un ders to od. The pre sen ce of au to an ti bo di es was re por ted in pso ri a sis pa ti ents wit ho ut any cli ni cal symptoms. 17 Many au to im mu ne di se a ses ha ve be en re por ted to be as so ci a ted with pso ri a sis such as RA, syste mic lu pus ery the ma to sus (SLE), scle roder ma, mi xed con nec ti ve tis su e di se a se (MCTD), au to im mu ne thyro i di tis, per ni ci o us ane mi a, Sjogren's syndro me, and myast he ni a gra vis. 11 In this study, we ai med to in ves ti ga te an ti-CCP an ti bo di es in pa ti ents with PsV and PsA, and ho ped to con tribu te to the know led ge in im mu no pat ho ge ne sis of pso ri a sis. Sin ce the trig ge ring an ti gen in the pro posed im mu no lo gi cal mec ha nisms of pso ri a sis ha ve not be en comp le tely un ders to od yet, we in ves ti gated an ti-ne ut rop hil cytop las mic an ti body (AN CA) and an ti nuc le ar an ti body (ANA) in ad di ti on to anti-CCP to se arch for ot her pro bab le trig ge ring an tigens as well as trying to exc lu de ot her inf lam ma tory con nec ti ve tis su e di se a ses li ke SLE and MCTD that co uld be as so ci a ted with pso ri a sis in our ca ses.
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MA TE RI AL AND MET HODS
A to tal of 89 (39 ma les, 50 fe ma les) pa ti ents par tici pa ted in this study. Forty fo ur PsV (19 ma les, 25 fe ma les) and 45 PsA (20 ma les, 25 fe ma les) pa ti ents who had app li ed to der ma to logy and/or rhe u ma tology cli nics of Ga zi Uni ver sity Hos pi tal and to the rhe u ma to logy cli nic of Bas kent Uni ver sity Hos pital be ing di ag no sed with pso ri a sis cli ni cally and his to pa lo gi cally we re inc lu ded in this study. Thirty two he althy (15 ma les, 17 fe ma les) vo lun te ers who had ne it her pso ri a sis vul ga ris, pso ri a tic art hri tis nor any known au to im mu ne or inf lam ma tory di se a ses we re ta ken in to the he althy con trol gro up. Da te of the Hu man et hics com mit te e ap pro val is 27 Novem ber 2006, and ap pro val num ber is 341 for this study. Pa ti ents and the mem bers of the he althy con trol gro up we re in for med pri or to the study, and sig ned disc lo su re forms. Pso ri a sis pa ti ents with a de fi ned art hri tis re la ted to a known au to im mu ne di se a se, e.g. rhe u ma to id art hri tis (but not PsA), pati ents with po si ti ve rhe u ma to id fac tor (RF) test result, and pa ti ents who had ta ken long term TNF-α tre at ment we re exc lu ded from the study. No ne of the he althy vo lun te ers had RF po si ti vity eit her. Pati ents we re gro u ped ac cor ding to pso ri a sis are a and se ve rity in dex (PA SI) sco ring cri te ri a: PA SI sco res ≤10 we re eva lu a ted as mild, 10-20 we re eva lu a ted as mo de ra te, ≥20 we re eva lu a ted as se ve re di se a se. Pe rip he ral ve no us blo od samp les we re col lec ted and cen tri fu ged at 3000xg for 15 mi nu tes. Iso la ted se rum samp les we re kept at -20°C un til the as say day. In se rum samp les, an ti-CCP an ti bo di es we re stu di ed se mi-qu an ti ta ti vely with a com mer ci al ELI SA kit (an ti-CCP ELI SA, IgG, Eu ro im mun, Lü -beck Ger many) and au to an ti body ti ters in se rum samp les are cal cu la ted using ti ters of known standards supp li ed in the kit by me ans of a com pu terba sed sta tis tics prog ram cal led Mic ros ta. As an ad di ti o nal la bo ra tory pa ra me ter, we de ter mi ned AN CA and ANA pro fi les in our study gro up.
AN CA Pro fi le [an ti-pro te i na se 3 (PR3), an timye lo pe ro xi da se (MPO), an ti-elas ta se, an ti-lac tofer rin, an ti-ca tep sin G, Bac te ri ci dal/per me a bi lityin cre a sing pro te in (BPI), AN CA mix tu re] was studi ed qu a li ta ti vely with a com mer ci ally ava i lab le ELI SA kit (AN CA Pro fi le ELI SA, IgG, Eu ro immun). ANA pro fi le [an ti-SS-A (an ti-Ro), an ti-SS-B (an ti-La), an ti-Ro52, an ti-Sm, an ti-nRNP/Sm, anti-Scl 70, an ti-PM-Scl, an ti-Jo1, an ti-cen tro mer pro te in B, an ti-dsDNA, an ti-his to ne an ti body, anti-ri bo so mal P pro te in, an ti-nuc le o so me an ti body, an ti-mi toc hon dri al an ti body-AMA-2] was stu di ed with a com mer ci al im mu nob lot ting as say (ANA Pro fi le 3, IgG, EU RO LI NE, Eu ro im mun) whe re anti-Sm stands for an ti-Smith an ti gen, an ti-nRNP for an ti-nuc le ar ri bo nuc le op ro te in, an ti-Scl for an tiscle ro der ma, an ti-PM for an ti-poly myo si tis. The re sults we re as ses sed qu a li ta ti vely vi su ally as well as di gi tally using EU RO LI NE Scan prog ram.
STA TIS TI CAL ANALY SIS
Da ta analy sis was per for med by using SPSS for Win dows, ver si on 11.5 (SPSS Inc., Chi ca go, IL, Uni ted Sta tes). Whi le con ti nu o us va ri ab les we re shown as me an±stan dard de vi a ti on, ot her wi se, num ber of ca ses and (%) was used for no mi nal data. The me an dif fe ren ces bet we en gro ups we re com pa red by Stu dent's t test. No mi nal da ta we re eva lu a ted by Pe ar son's Chi-squ a re or Fis her's exact test; whe re ap prop ri a te. A p va lu e less than 0.05 was con si de red sta tis ti cally sig ni fi cant.
RE SULTS
In the study gro up, 39 (43.82%) we re ma les and 50 (56.17%) we re fe ma les. The me an age was 46.7±13.5 (19-78) ye ars. In the he althy con trol group, 15 (46.87%) we re ma les and 17 (%53.13) we re fe ma les; the me an age of this gro up was 37.7±11.6 (18-64) ye ars (Tab le 1). Whi le the re was no sta tisti cally sig ni fi cant dif fe ren ce bet we en gro ups re garding for gen der dis tri bu ti on (p=0.766), the me an age in study gro up was sta tis ti cally sig ni fi cantly hig her than the he althy con trol gro up (p<0.001). Ho we ver this dif fe ren ce had no ef fects on the para me ters of this study. Ac cor ding to der ma to lo gi cal exa mi na ti on inc lu ding PA SI sco ring, 63 (70%) pati ents with PsV had mild, 17 (19%) had mo de ra te and 9 (10%) had se ve re di se a se, whi le in PsA pa tients 27 (79%) had mild, 6 (18%) had mo de ra te and 1 (3%) had se ve re di se a se. An ti-CCP an ti bo di es were high-po si ti ve (>10 Re la ti ve Units-RU/mL) in 5 pa ti ents and was low-po si ti ve (5-10 RU/mL) in 3 pa ti ents. That is, sum of 8 (8.9%) pa ti ents we re detec ted as an ti-CCP po si ti ve and 2 of the se 8 pa tients had pso ri a tic art hri tis.
No ne of the pa ti ents in our study gro up had AN CA po si ti vity. When ANA pro fi le was eva lu ated: a 43-ye ar-old fe ma le pa ti ent with PsA was AMA-M2(+), an ti-Ro52(++), an ti-nuc le o so me (+), an ti-ds DNA(+); a 38-ye ar-old ma le PsV pa ti ent (wit ho ut PsA) had sus pi ci o us (gray zo ne) an tinRNP/-Sm po si ti vity; a 33-ye ar-old fe ma le PsV pati ent had an ti-SS-A (++) (Tab le 2). We did not de tect an ti-CCP, AN CA or ANA po si ti vity in the he althy con trol gro up.
DIS CUS SI ON
In our study, an ti-CCP an ti bo di es we re high-po siti ve in 5 pa ti ents and low -po si ti ve in 3 pa ti ents. In to tal, 8 (8.9%) pa ti ents we re de tec ted as po si ti ve and 2 (5.8%) of the se 8 pa ti ents had pso ri a tic arthri tis. In a study by Ale ni us et al., an ti-CCP an tibo di es we re fo und to be mo re pre va lent in pa ti ents with PsA than in pa ti ents wit ho ut art hri tis. 11 Af ter 4-ye ar fol low-up, most of the se pa ti ents ful fil led the A me ri can Col le ge of Rhe u ma to logy (ACR) crite ri a for RA. Both PsA and RA are qu i te com mon in the po pu la ti on, so the re is a pos si bi lity that the pa ti ents ha ve both PsA and RA. The se da ta shows the comp le xity in dif fe ren ti al di ag no sis bet we en the two di se a ses. Con trary to the re sults of Ale nius et al., we fo und out that 13.6% of pso ri a sis pa tients wit ho ut PsA we re po si ti ve for an ti-CCP an ti bo di es. 11 Ale ni us gro up had in ves ti ga ted rhe uma to id fac tor (RF) and eryt hrocy te se di men ta ti on ra te, but did not per form PA SI sco ring and did not as say for ANA and AN CA au to im mu ne an ti bo di es; they re por ted that pa ti ents with PsA po si ti ve for an ti-CCP an ti bo di es mo re of ten had pol yart hri tic di se a se.
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Ab del Fat tah et al. tes ted 40 PsA, 40 pso ri a sis wit ho ut art hri tis, 40 RA and 40 he althy con trols for an ti-CCP an ti bo di es, and fo und that an ti-CCP po si ti vity was 17.5% in PsA and 85% in RA pa tients in the ir study gro up. Pe rip he ral and axi al jo int eva lu a ti on was per for med ac cor ding to Moll and Wright cri te ri a, mo di fi ed by Hel li well et al. 18 No sta tis ti cally sig ni fi cant dif fe ren ces we re fo und bet we en dif fe rent gro ups re gar ding the ir age and gender. In our study, the fe ma le/ma le ra ti o was fo und to be 1.43/1 in the PsA gro up; ho we ver fe male/ma le ra ti o was 0.91/1 in PsV pa ti ents who had no art hri tis and who we re not suf fe ring from jo int pa in. When pso ri a sis pa ti ents with and wit ho ut arthri tis we re as ses sed re gar ding to age, gen der, di sea se du ra ti on and PA SI sco ring, no sta tis ti cally 
Deri ve Zührevi Hastalıklar sig ni fi cant dif fe ren ce we re ob ser ved bet we en the gro ups. 3 We ob ser ved mild pso ri a sis in 57.7% of PsV pa ti ents wit ho ut PsA and in 79% of PsA pa tients. This can be re la ted to the fact that PsA pa tients ta ke syste mic tre at ment much mo re com monly com pa red to PsV pa ti ents as well as to the slight per so nal dif fe ren ces in eva lu a ti on of the pa ti ents by physi ci ans. In the ir conc lu si on Ab del Fat tah et al. re por ted that an ti-CCP-po si ti ve PsA pa ti ents might suf fer from an over lap with a precli ni cal form of RA and in such ca ses an ti-CCP tes ting co uld help in se lec ti on of pa ti ents who might ne ed fol low-up, es pe ci ally wit hA me ri can Rhe uma tism As so ci a ti on (ARA) cri te ri a. 3 Ma e ji ma et al. exa mi ned an ti-CCP in 15 pa tients with PsA, and com pa red with 18 con trol pa tients who had ot her types of pso ri a sis. 19 Si mi lar to our re sults, the re we re no sig ni fi cant dif fe ren ces in PA SI sco res, du ra ti on of ill ness, se di men ta ti on and CRP le vels among pa ti ents with and wit ho ut an ti-CCP po si ti vity. Thre e PsA pa ti ents we re po si ti ve for an ti-CCP, but no ne of the con trol pa ti ents gave po si ti ve re sults. 19 The pre sen ce of an ti-CCP in PsA pa ti ents may in di ca te that they will de ve lop jse ve re jo int di se a se. 20 This sug gests that an ti-CCP wo uld be a mar ker of di se a se se ve rity.
Shi ba ta et al. eva lu a ted 16 PsA, 15 pso ri a sis, 9 RA pa ti ents and 11 he althy con trols. Un li ke our study, they de tec ted high ti ters of RF po si ti vity and an ti-CCP po si ti vity in 13% of PsA pa ti ents. 21 In a re cent pa per by Hel li well et al. re por ting the re sults of the Clas si fi ca ti on cri te ri a for Pso ri atic Art hri tis (CAS PAR) study, an ti-CCPs we re detec ted in 26/588 pa ti ents with PsA, 15/388 with pol yar ti cu lar va ri ety and 11/200 with non-pol yarti cu lar PsA. 18 The se da ta, in di ca ting that the occur ren ce of an ti-CCP was not li mi ted to the pol yart hri tis, con fir med tho se re por ted by anot her re cent study by Bog li o lo et al. They exa mi ned 102 PsA pa ti ents and fo und an ti-CCP po si ti vity in 16 pa ti ents who we re mostly af fec ted with symmet ric pol yart hri tis. In this po pu la ti on, 19/102 pa ti ents had RF and an ti-CCP was pre sent in 11 of them. Thus in PsA, the pre sen ce of an ti-CCP was not res tric ted to tho se with cli ni cal pic tu res re semb ling RA, and the re fo re it se e med to be un re li ab le as a mar ker of RA. Ho we ver, as in RA, the pre sen ce of an ti-CCP was as so ci a ted with an in cre a sed num ber of ero si ons, pro bably ref lec ting a mo re se ve re outco me. 20 Dalmády et al. in ves ti ga ted the pre va len ce of an ti-MCVs (mu ta ted cit rul li na ted vi men tin) in PsA and PsO (pso ri a sis wit ho ut jo int symptoms). 22 They fo und that the an ti-MCV le vels in the PsA pa ti ents we re sig ni fi cantly hig her than tho se in the PsO gro up. The ir re sults sug gest that an ti-MCVs can be used as no vel mar kers in the di ag no sis of PsA and in a sub set of PsO pa ti ents.
Ro sen berg et al. re por ted that they fo und granu locy te-spe ci fic ANA in 7 of 52 PsA ca ses, but not in any of ot her pso ri a sis pa ti ents. 23 ANA was po siti ve in one pa ti ent with pso ri a sis. The se re sults are pa ral lel to our fin dings. In our study, a 43-ye ar-old fe ma le pa ti ent with PsA was AMA-M2(+), an tiRo52(++), an ti-nuc le o so me (+), an ti-ds DNA(+); a 38-ye ar-old ma le pa ti ent with PsV but not PsA, had a sus pi ci o us (gray zo ne) an ti-nRNP/-Sm po siti vity; a 33-ye ar-old fe ma le pa ti ent with PsV was po si ti ve for an ti-SS-A. AMA-M2 po si ti vity is ge nerally tho ught to be as so ci a ted with chro nic li ver dise a ses or he pa ti tis B car ri er sta te. On the ot her hand, an ti-Ro-52, an ti-dsDNA and an ti-nuc le o some po si ti vity sug gest that this pa ti ent must be eva lu a ted in terms of SLE-li ke in the study of Zal la and Mul ler. 24 Zal la and Mul ler iden ti fi ed 42 ca ses of SLE among 9400 pso ri a sis pa ti ents in a 10-ye ar ret rospec ti ve study, with pre va len ce of SLE in 0.69%. 24 Alt ho ugh our pa ti ent who was an ti-dsDNA po si tive had no cli ni cal evi den ce of SLE yet, we de ci ded that she sho uld be ta ken in to fol low-up for a possib le SLE in the fu tu re.
An ti-nRNP se ro po si ti vity is se en with a high fre qu ency in pa ti ents with mi xed con nec ti ve tis sue di se a se. In our study, a 38-ye ar-old ma le pa ti ent with PsV wit ho ut art hri tis had sus pi ci o us an tinRNP po si ti vity in re pe a ted as says; the re fo re, we to ok him un der fol low-up for a pro bab le mi xed con nec ti ve tis su e di se a se in the fu tu re.
Singh et al. stu di ed a to tal of 118 pso ri a sis pati ents in or der to find the pre va len ce of va ri o us au-Dermatology and Venerology Atak Yücel et al.
to an ti bo di es in pso ri a sis pa ti ents and its cor re la ti on with gen der, age, and type. 25 RF, an ti-dsDNA, ANA and an ti-thyro id mic ro so mal an ti bo di es (TMA) were stu di ed. Pso ri a sis pa ti ents inc lu ded 75 ca ses (63.6%) of pla qu e pso ri a sis, 27 ca ses (22.9%) of palmop lan tar, 6 ca ses (5.1%) of pso ri a tic eryt hro derma, 4 ca ses (3.4%) of pso ri a tic art hri tis, and 3 ca ses (2.5%) gut ta te pso ri a sis. A to tal of 34 (28.8%) ca ses of pso ri a sis we re fo und to be po si ti ve for at le ast one of the au to an ti bo di es. ANA po si ti vity was mo re frequ ent among ma les (57.1 vs. 42.9%) whe re as an ti-TMA po si ti vity was mo re fre qu ent in fe ma les (66.7 vs. 33.3%). 25 It was conc lu ded that eit her the se auto an ti bo di es we re fo und to be pre sent in pso ri a sis pa ti ents or la tent au to im mu ne di se a ses de ve lo ped in pso ri a sis pa ti ents wit ho ut any cli ni cal symptoms. Only one fe ma le pa ti ent was po si ti ve for an tidsDNA in our study gro up, and we to ok her un der fol low-up for a pos sib le SLE in the fu tu re.
An to nel li et al. tes ted thyro id au to im mu nity in PsA pa ti ents, and re por ted that 28% of his pa tients we re po si ti ve for an ti-TMA. 26 Ku tuk cu ler et al. analy zed va ri o us au to an ti bodi es in pa ti ents with pso ri a sis, and re por ted that 5.8% of ca ses we re po si ti ve for RF, only one ca se was po si ti ve for ANA and dsDNA. 27 Si mi lar to their re sults, only a 33-ye ar-old fe ma le PsA pa ti ent was fo und to be an ti-SS-A po si ti ve in our study. They fo und P-AN CA po si ti vity in 33.3% of the ir pa ti ents and re por ted that the re sults of the ir study had sup por ted au to im mu nity in the pat ho ge ne sis of pso ri a sis vul ga ris whi le no ne of our pa ti ents had AN CA se ro po si ti vity.
Jan jum rat sang et al. in ves ti ga ted so me im muno lo gi cal pa ra me ters [ANA, an ti-dsDNA, an ti-Ro and an ti-nuc le ar ri bo nuc le op ro te in (nRNP)] in pso ri a sis pa ti ents using di rect im mu nof lu o res cence. 17 Of 300 ca ses com pri sing 189 men (62.9%) and 111 wo men (37.1%), 17 (5.7%; 10 men, se ven women) we re po si ti ve for at le ast one of the se im muno lo gi cal pa ra me ters. 17 The exact ca u se of au to im mu nity in pso ri a sis is not cle ar. Atas si and Ca sa li re por ted that it might be du e to the over lap ping of the lo ca ti ons of so me po tent au to im mu ne ge nes and pso ri a sis ge nes. 28 Alte ra ti on in self-to le rant pro te ins may al so eli cit auto im mu ne res pon ses or mo le cu lar mi micry is sup po sed to be one of the ca u ses for au to im mu nity, du e to the struc tu ral si mi la rity bet we en strep tococ cal M pro te in with ke ra tin 17 pro te in of skin. 29, 30 In conc lu si on, pa ti ents with PsA had less frequ ent an ti-CCP po si ti vity com pa red to the pre sent da ta in the li te ra tu re in our study. AN CA po si ti vity was not de tec ted in any of our pa ti ents. Only one fe ma le pa ti ent with PsA was AMA-M2(+), an ti-Ro52(++), an ti-nuc le o so me (+), an tids DNA(+); one ma le PsV pa ti ent had sus pi ci o us an ti-nRNP/-Sm po si ti vity, and one fe ma le PV pati ent was po si ti ve for an ti-SS-A. Con se qu ently, it se ems that lar ger sca le and mul ti cen te red stu di es are ne e ded in or der to en ligh ten the ro le of an ti-CCP an ti bo di es and ot her au to an ti bo di es in the im mu no pat ho ge ne sis of pso a ri a sis and pso ri a tic art hri tis. 
